Aerosol Tobramycin 300 mg single dose in adult patient with cystic fibrosis: pilot study of antimicrobial activity [Tobramicina 300 mg aerosol in monosomministrazione in pazienti adulti con Fibrosi Cistica: studio pilota sull'attivita' antimicrobica]
Phase of Trial: Phase III
Latest Information Update: 25 Aug 2012
At a glance
- Drugs Tobramycin (Primary)
- Indications Bacterial infections; Cystic fibrosis-associated respiratory tract infections
- Focus Biomarker; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 23 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.